Table 1.

Summary of the clinical condition of oral lesion and laboratory data

	Normal range	First visit to examine oral lesions	Follow-up of oral lesions	Admission for recurrent HCC	Before liver transplantation	Liver transplantation	After liver transplantation	Before DAA treatment	Start of DAA treatment	SVR12	SVR24
Date		Jul. 17, 2008	Jul. 10, 2010	Aug. 7, 2014	Jan. 14, 2015	Mar. 10, 2015	Jun. 3, 2015	Feb. 15, 2016	Feb. 29, 2016	Aug. 16, 2016	Nov. 7, 2016
Age, years		53	55	59	60	60	60	61	61	61	61
Clinical condition of OLP		Presence	Exacerbation	Presence	Presence	Presence	Improvement	Improvement		Disappearance	Disappearance
Sites of OLP		Lower lip	Lower lip and buccal mucosa	Lower lip and buccal mucosa	Lower lip and buccal mucosa	Lower lip and buccal mucosa	Lower lip and buccal mucosa	Lower lip and buccal mucosa		OLP disappearance	OLP disappearance
Laboratory data
AST, U/L	13–33	71	50	36	35		14	28		21	21
ALT, U/L	6–30	87	58	43	44		11	24		23	28
T. protein, g/dL	6.70–8.30	6.5	7	6.99	6.5		6	6.8		6.6	6.6
Albumin, g/dL	4.00–5.00	3.22	ND	3.23	3.3		3.5	4.4		4	4.1
Gamma-GTP, U/I	10–47	457	351	181	57		109	199		187	209
ALP, U/L	115–359	1,086	973	1,532	793		463	469		388	367
T. bilirubin, mg/dL	0.30–1.20	0.92	ND	0.88	1.20		0.5	0.7		0.8	1
D. bilirubin, mg/dL	≤0.60	0.27	ND	0.21	0.30		0.1	0.2		0.2	0.2
T. cholesterol, mg/dL	128–219	110	124	214	150		ND	ND		ND	ND
Hb, g/dL	11.0–15.0	15.4	ND	14.7	14.9		11.4	15.6		16.1	15.1
PLT, ×10−4/µL	13.0–36.0	9.9	ND	5.3	6.0		12.1	9.4		13.7	11.4
AFP, ng/mL	≤8.7	41.9	29.6	215.7	206.7		ND	3.0		2	2
FT4, ng/dL	0.88–1.56	ND	ND	ND	ND		ND	1.44		0.64	1.01
TSH, µIU/L	0.210–3.850	ND	ND	ND	ND		ND	3.4		30.36	10
FBS, mg/dL	80–109	128	102	82	107		ND	ND		ND	ND
HbA1c, %	4.9–6.0	5	ND	4.9	ND		ND	5.8		5.9	5.9
HCV viral load, logIU/mL		6.8	6.9	ND	ND		ND	7.24		Negative	Negative

T., total; D., direct; ND, not determined.